Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.78 |
| ▸ | AGER | Q15109 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724625 | 0.93 | AR (0.87) | ARMAOB | |
| SCHEMBL28448185 | 0.93 | AR (0.87) | ARMAOB | |
| SCHEMBL1104918 | 0.91 | AR (0.83) | ARMAOBAGER | |
| SCHEMBL29724499 | 0.89 | AR (1.00) | ARMAOBAGER | |
| SCHEMBL29724376 | 0.89 | AR (1.00) | ARMAOBAGER | |
| SCHEMBL28897388 | 0.89 | AR (1.00) | ARMAOBAGER | |
| SCHEMBL28441293 | 0.89 | AR (1.00) | ARMAOBAGER | |
| SCHEMBL29724359 | 0.88 | AR (0.79) | ARMAOBAGER | |
| SCHEMBL1104924 | 0.88 | AR (1.00) | ARMAOBAGERNPC1CASP3 | |
| SCHEMBL29724494 | 0.88 | AR (1.00) | ARMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230392121-A1 | HYDROGELS FOR CELL CULTURE | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-12-07 | — | — | US | claimed |
| EP-4208534-A1 | HYDROGELS FOR CELL CULTURE | Katholieke Universiteit Leuven (BE) | 2023-07-12 | — | — | EP | claimed |
| WO-2022049154-A1 | HYDROGELS FOR CELL CULTURE | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-10 | — | — | WO | claimed |
| US-20210077444-A1 | Methods of Inducing Metabolic Maturation of Human Pluripotent Stem Cells-Derived Hepatocytes | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-03-18 | — | — | US | claimed |
| US-20170266145-A1 | METHODS OF INDUCING METABOLIC MATURATION OF HUMAN PLURIPOTENT STEM CELLS-DERIVED HEPATOCYTES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-09-21 | — | — | US | claimed |
| US-8952054-B2 | Small molecule inhibitors of MUC1 and methods of identifying the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-02-10 | — | — | US | claimed |
| EP-2548017-A2 | SMALL MOLECULE INHIBITORS OF MUC1 AND METHODS OF IDENTIFYING THE SAME | GENUS ONCOLOGY, LLC (US) | 2013-01-23 | — | — | EP | claimed |
| US-20110251246-A1 | SMALL MOLECULE INHIBITORS OF MUC1 AND METHODS OF IDENTIFYING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | claimed |
| WO-2011115819-A2 | SMALL MOLECULE INHIBITORS OF MUC1 AND METHODS OF IDENTIFYING THE SAME | GENUS ONCOLOGY, LLC (US) | 2011-09-22 | — | — | WO | claimed |
| US-20040106216-A1 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2004-06-03 | — | — | US | claimed |
| EP-1378751-A2 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | Toyo Boseki Kabushiki Kaisha (JP) | 2004-01-07 | — | — | EP | claimed |
| US-12630804-B2 | Blood brain barrier model | University of Lancashire (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20260083728-A1 | COMPOUNDS FOR TREATING INFECTIONS WITH PARASITIC PROTOZOA | OHIO STATE INNOVATIION FOUND (US) | 2026-03-26 | — | — | US | disclosed |
| US-12466895-B2 | Antibodies against the MUC1-c/extracellular domain (MUC1-C/ECD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4590676-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6207404-B1 | SUBJECTING THE CYTOCHROME P450 ENZYME AND THE COUMARIN BASED COMPOUND TO CONDITIONS WHEREBY THE CYTOCHROME P450 ENZYME CATALYZES THE CONVERSION OF THE COUMARIN BASED COMPOUND TO A FLUORESCENT PRODUCT | GENTEST CORPORATION | 2001-03-27 | — | — | US | disclosed |
| WO-2001020025-A2 | POLYMORPHISMS IN THE HUMAN CYP3A4 AND CYP3A7 GENES AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-6143492-A | COMPOUND USEFUL AS AN OPTICAL PROBE; DRUG SCREENING | AURORA BIOSCIENCES CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000035900-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | AURORA BIOSCIENCES CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251246-A1 | SMALL MOLECULE INHIBITORS OF MUC1 AND METHODS OF IDENTIFYING THE SAME | MUC1, EPCAM, CD44 | AR 4148/4885MAOB 4859/4885AGER 1087/4885 |
| US-12630804-B2 | Blood brain barrier model | PGF, FLT4, VEGFA | AR 3253/4885MAOB 4481/4885AGER 1120/4885 |
| US-20260083728-A1 | COMPOUNDS FOR TREATING INFECTIONS WITH PARASITIC PROTOZOA | CLIC1, AOC2, CFTR | AR 3814/4885MAOB 1576/4885AGER 4697/4885 |
| US-12466895-B2 | Antibodies against the MUC1-c/extracellular domain (MUC1-C/ECD) | MUC1, EPCAM, SDC1 | AR 2221/4885MAOB 4870/4885AGER 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.